Come up with a name for your new list and we'll add to it:
Compass Pathways raised a round of funding on October 03, 2018. Investors include
Atai Life Sciences.
Compass Pathways' initiative is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression. …